US equities |
NVDA $237.08 ▲+1.34% MU $1,058.96 ▼-1.48% SPCX $164.73 ▲+3.63% TSLA $376.20 ▲+1.52% MSFT $527.80 ▲+1.98% INTC $116.12 ▼-2.69% SNDK $1,715.42 ▼-0.27% AMD $628.65 ▼-0.83%
FinancialContent

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

2.900 -0.080 (-2.68%)
Delayed Quote Updated: 9:59 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia ↗
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia.  
Via Benzinga
News headline image
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for SAB Biotherapeutics ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Nasdaq Falls 100 Points; AT&T Posts Upbeat Earnings ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 33,520.17 while the NASDAQ fell 0.75% to 13,214.04. The... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate ↗
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in... 
Via Benzinga
News headline image
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology Study ↗
SAB Biotherapeutics Inc (NASDAQ: SABS) announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a fully human immunotherapeutic being developed for delaying... 
Via Benzinga
News headline image
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >